Stratos Wealth Partners’s TherapeuticsMD TXMD Stock Holding History

Stratos Wealth Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-202	Closed	-$4K	–	1299
2022 Q1	$4K	Sell	202 -65	-24%	-$1.02K	﹤0.01%	1265
2021 Q4	$5K	Hold	267	–	–	﹤0.01%	1252
2021 Q3	$10K	Hold	267	–	–	﹤0.01%	1175
2021 Q2	$16K	Hold	267	–	–	﹤0.01%	1180
2021 Q1	$18K	Hold	267	–	–	﹤0.01%	1109
2020 Q4	$16K	Buy	+267	New	+$18.2K	﹤0.01%	1070
2019 Q4	–	Sell	-200	Closed	-$36K	–	1009
2019 Q3	$36K	Hold	200	–	–	﹤0.01%	947
2019 Q2	$26K	Hold	200	–	–	﹤0.01%	949
2019 Q1	$49K	Sell	200 -40	-17%	-$10.6K	﹤0.01%	921
2018 Q4	$46K	Buy	240 +30	+14%	+$7.32K	﹤0.01%	856
2018 Q3	$69K	Buy	+210	New	+$64.3K	﹤0.01%	1313
2018 Q2	–	Sell	-160	Closed	-$39K	–	2468
2018 Q1	$39K	Hold	160	–	–	﹤0.01%	1703
2017 Q4	$48K	Buy	+160	New	+$44.5K	﹤0.01%	1535

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Stratos Wealth Partners's TXMD Position: Q2 2022 in Review

Stratos Wealth Partners sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 202 shares — an estimated $4K sold.

Stratos Wealth Partners first reported a position in TXMD in Q4 2017 and held it in 13 quarters. The position peaked at $69K in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Stratos Wealth Partners reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Stratos Wealth Partners sold 202 TherapeuticsMD shares in Q2 2022, an estimated $4K.
Stratos Wealth Partners first reported a position in TherapeuticsMD in Q4 2017 and held it in 13 quarters.
Stratos Wealth Partners's TherapeuticsMD position peaked at $69K in Q3 2018.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Stratos Wealth Partners's 13F filing for Q2 2022, filed 22 Jul 2022.